Inluriyo adn Verzemio for breast cancer – pro

Abemaciclib 100 mg tab and imlunestrant 200 mg were FDA-approved based on the Phase 3 EMBER-3 trial.

Jhaveri K, Neven P, Casalnuovo M , Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. Annals of Oncology, 2025; 37, 532-543

Inluriyo Prescribing Information 2026

Categories

Blog Archives